Its levels seemingly do not vary with anti-IL-5 (mepolizumab) or anti-IL-5R (benralizumab) therapy [12], although some variability has been reported, despite no apparent consequence on functional and asthma control parameters [13]. This evidence concerns the gene IL5 and asthma.